article thumbnail

Oral Protein / Peptide-based Drugs: Addressing Key Unmet Needs Across Disease Indications

Roots Analysis

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Pipeline Overview of Oral Peptide and Protein-based Therapeutics. Oral Protein / Peptide-based Drugs. Oral Protein / Peptide-based Drugs.

Protein 52
article thumbnail

USPTO issues notice of allowance for Windtree’s SERCA2A activators

Pharmaceutical Technology

The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for Windtree Therapeutics’ patent application covering a group of SERCA2A [a key protein in the cycle of heart failure] activators with a dual mechanism.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BeiGene and partners to offer Brukinsa in low-income countries

Pharmaceutical Technology

It delivers sustained BTK protein inhibition by optimising bioavailability, half-life and selectivity. Brukinsa is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor that will be used to treat chronic lymphocytic leukaemia (CLL) in adult patients.

article thumbnail

China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL

Pharmaceutical Technology

The small molecule Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity.

article thumbnail

BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers

Pharmaceutical Technology

Brukinsa is a small-molecule Bruton’s tyrosine kinase (BTK) inhibitor specially designed for delivering sustained and targeted BTK protein inhibition by optimising bioavailability, half-life, and selectivity. The regulatory approval for the BTK inhibitor to treat CLL was based on Phase III SEQUOIA and ALPINE clinical trials.

Marketing 130
article thumbnail

PROTACs show promise for cancer treatment

Pharmaceutical Technology

Development of PROTACs (PROteolysis TArgeting Chimeras) has advanced fairly rapidly as excitement grows over their potential to selectively degrade proteins that are involved in various diseases, including cancer. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.

Protein 130
article thumbnail

EC approves BeiGene’s chronic lymphocytic leukaemia therapy

Pharmaceutical Technology

It was specifically designed to provide targeted and sustained BTK protein inhibition by optimising bioavailability, selectivity, and half-life. The small-molecule Bruton’s tyrosine kinase (BTK) inhibitor, Brukinsa has been approved to treat treatment-naïve (TN) or relapsed/refractory (R/R) CLL in adult patients.